Interleukin- |
Kim, Sun Jong
(Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Kunkuk University Hospital)
Lee, Siyoung (Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University) Kwak, Areum (Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University) Kim, Eunsom (Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University) Jo, Seunghyun (Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University) Bae, Suyoung (Department of Bioequivalence Division for Drug Evaluation, Ministry of Food and Drug Safety) Lee, Youngmin (Department of Medicine, Pusan Paik Hospital, College of Medicine, Inje University) Ryoo, Soyoon (Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University) Choi, Jida (Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University) Kim, Soohyun (Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University) |
1 | Astiz ME, Rackow EC. 1998. Septic shock. Lancet 351: 1501- 1505. DOI ScienceOn |
2 | Alves-Filho JC, Sonego F, Souto FO, Freitas A, Verri Jr WA, Auxiliadora-Martins M, et al. 2010. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat. Med. 16: 708-712. DOI ScienceOn |
3 | Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al. 1995. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, doubleblind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273: 934-941. DOI ScienceOn |
4 | Alves-Filho JC, Freitas A, Souto FO, Spiller F, Paula-Neto H, Silva JS, et al. 2009. Regulation of chemokine receptor by Toll-like receptor 2 is critical to neutrophil migration and resistance to polymicrobial sepsis. Proc. Natl. Acad. Sci. USA 106: 4018-4023. DOI ScienceOn |
5 | Bae S, Kim YG, Choi J, Hong J, Lee S, Kang T, et al. 2012. Elevated interleukin-32 expression in granulomatosis with polyangiitis. Rheumatology (Oxford) 51: 1979-1988. DOI |
6 | Choi J, Bae S, Hong J, Ryoo S, Jhun H, Hong K, et al. 2010. Paradoxical effects of constitutive human IL-32{gamma} in transgenic mice during experimental colitis. Proc. Natl. Acad. Sci. USA 107: 21082-21086. DOI ScienceOn |
7 | Choi JD, Bae SY, Hong JW, Azam T, Dinarello CA, Her E, et al. 2009. Identification of the most active interleukin-32 isoform. Immunology 126: 535-542. DOI ScienceOn |
8 | Cohen J. 2002. The immunopathogenesis of sepsis. Nature 420: 885-891. DOI ScienceOn |
9 | Ellis TN, B eaman B L. 2004. I nterferon-gamma a ctivation o f polymorphonuclear neutrophil function. Immunology 112: 2-12. DOI ScienceOn |
10 | Cohen J, Carlet J. 1996. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit. Care Med. 24: 1431-1440. DOI ScienceOn |
11 | Dahl CA, Schall RP, He HL, Cairns JS. 1992. Identification of a novel gene expressed in activated natural killer cells and T cells. J. Immunol. 148: 597-603. |
12 | Doherty GM, Lange JR, Langstein HN, Alexander HR, Buresh CM, Norton JA. 1992. Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. J. Immunol. 149: 1666-1670. |
13 | Goda C, Kanaji T, Kanaji S, Tanaka G, Arima K, Ohno S, Izuhara K. 2006. Involvement of IL-32 in activation-induced cell death in T cells. Int. Immunol. 18: 233-240. DOI |
14 | Fisher Jr CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. 1996. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334: 1697-1702. DOI ScienceOn |
15 | Fitzgerald KA, Rowe DC, Golenbock DT. 2004. Endotoxin recognition and signal transduction by the TLR4/MD2- complex. Microbes Infect. 6: 1361-1367. DOI ScienceOn |
16 | Freise H, Bruckner UB, Spiegel HU. 2001. Animal models of sepsis. J. Invest. Surg. 14: 195-212. DOI |
17 | Guha M, Mackman N. 2001. LPS induction of gene expression in human monocytes. Cell Signal. 13: 85-94. DOI ScienceOn |
18 | Hack CE, Aarden LA, Thijs LG. 1997. Role of cytokines in sepsis. Adv. Immunol. 66: 101-195. DOI |
19 | Hotchkiss RS, Karl IE. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348: 138-150. DOI ScienceOn |
20 | Heinhuis B, Koenders MI, van Riel PL, van de Loo FA, Dinarello CA, Netea MG, et al. 2010. Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade. Ann. Rheum. Dis. 70: 660-667. |
21 | Hong J, Bae S, Kang Y, Yoon D, Bai X, Chan ED, et al. 2009. Suppressing IL-32 in monocytes impairs the induction of the proinflammatory cytokines TNFalpha and IL-1beta. Cytokine 49: 171-176. |
22 | Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. 2009. The sepsis seesaw: tilting toward immunosuppression. Nat. Med. 15: 496-497. DOI ScienceOn |
23 | Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, et al. 2006. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 103: 3298-3303. DOI ScienceOn |
24 | Kobayashi H, Yazlovitskaya EM, Lin PC. 2009. Interleukin-32 positively regulates radiation-induced vascular inflammation. Int. J. Radiat. Oncol. Biol. Phys. 74: 1573-1579. DOI ScienceOn |
25 | Kawai T, Akira S. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11: 373-384. DOI ScienceOn |
26 | Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. 2005. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 22: 131-142. |
27 | Kobayashi H, Huang J, Ye F, Shyr Y, Blackwell TS, Lin PC. 2010. Interleukin-32beta propagates vascular inflammation and exacerbates sepsis in a mouse model. PLoS One 5: e9458. DOI ScienceOn |
28 | Koh GC, Peacock SJ, van der Poll T, Wiersinga WJ. 2011. The impact of diabetes on the pathogenesis of sepsis. Eur. J. Clin. Microbiol. Infect. Dis. 31: 379-388. |
29 | Meyer N, Zimmermann M, Burgler S, Bassin C, Woehrl S, Moritz K, et al. 2010. IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. J. Allergy Clin. Immunol. 125: 858-865. DOI ScienceOn |
30 | Marshall JC, Cook D J, C hristou N V, B ernard G R, S prung CL, Sibbald WJ. 1995. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit. Care Med. 23: 1638-1652. DOI ScienceOn |
31 | Martin GS, Mannino DM, Eaton S, Moss M. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348: 1546-1554. DOI ScienceOn |
32 | Mastroianni CM, Lichtner M, Mengoni F, D'Agostino C, Forcina G, d'Ettorre G, et al. 1999. Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1-infected patients. AIDS 13: 883-890. DOI ScienceOn |
33 | Nakayama M, Niki Y, Kawasaki T, Takeda Y, Horiuchi K, Sasaki A, et al. 2012. Enhanced susceptibility to lipopolysaccharideinduced arthritis and endotoxin shock in interleukin-32 alpha transgenic mice through induction of tumor necrosis factor alpha. Arthritis Res. Ther. 14: R120. DOI |
34 | Remick DG. 2007. Pathophysiology of sepsis. Am. J. Pathol. 170: 1435-1444. DOI ScienceOn |
35 | Netea MG, van der Meer JW, van Deuren M, Kullberg BJ. 2003. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol. 24: 254-258. DOI ScienceOn |
36 | Nishida A, Andoh A, Inatomi O, Fujiyama Y. 2009. Interleukin-32 expression in the pancreas. J. Biol. Chem. 284: 17868-17876. DOI ScienceOn |
37 | Polk Jr HC, Cheadle WG, Livingston DH, Rodriguez JL, Starko KM, Izu AE, et al. 1992. A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. Am. J. Surg. 163: 191-196. DOI ScienceOn |
38 | Riedemann NC, Guo RF, Ward PA. 2003. Novel strategies for the treatment of sepsis. Nat. Med. 9: 517-524. DOI ScienceOn |
39 | Shoda H, Fujio K, Yamaguchi Y, Okamoto A, Sawada T, Kochi Y, Yamamoto K. 2006. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res. Ther. 8: R166. DOI ScienceOn |
40 | Ryoo S, Lee S, Jo S, Kwak A, Kim E, Lee J, et al. 2014. Effect of lipopolysaccharide (LPS) on mouse model of steroidinduced avascular necrosis in the femoral head (ANFH). J. Microbiol. Biotechnol. 24: 394-400. DOI ScienceOn |
41 | Schlag G, Redl H, Davies J, Haller I. 1994. Anti-tumor necrosis factor antibody treatment of recurrent bacteremia in a baboon model. Shock 2: 10-18; discussion 19-22. DOI |
42 | Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim- Mitsuyama S, et al. 2007. Epithelial overexpression of interleukin- 32alpha in inflammatory bowel disease. Clin. Exp. Immunol. 149: 480-486. DOI ScienceOn |
![]() |